Literature DB >> 6086711

Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections.

V A Sundqvist, A Linde, B Wahren.   

Abstract

The subclass specificities of antiviral immunoglobulin G (IgG) produced in response to herpes simplex and varicella-zoster virus infections were investigated. IgG1 and IgG3 with anti-herpes simplex virus activity were seen in patients with primary and reactivated disease, as well as in healthy seropositive subjects and in immunoglobulin preparations. IgG4 was occasionally seen alone or together with IgG1 and IgG3 in patients. In varicella, IgG3-specific antiviral antibodies were predominant, whereas in zoster, IgG1 was the dominant subclass.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6086711      PMCID： PMC271254          DOI： 10.1128/jcm.20.1.94-98.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Use of protein A-treated sera in unmasking herpes simplex virus type 1 (HSV-1) immunoglobulin A and identifying HSV-1 immunoglobulin G as the predominant neutralizing antibody.

Authors:  J J Ratner; B A Sanford; K O Smith
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

Review 2.  Immunoglobulin structure and effector functions.

Authors:  J L Winkelhake
Journal:  Immunochemistry       Date:  1978-09

3.  Complement-fixing antigens of herpes simplex virus types 1 and 2: reactivity of capsid, envelope, and soluble antigens.

Authors:  M L Martin; E L Palmer; R E Kissling
Journal:  Infect Immun       Date:  1972-02       Impact factor: 3.441

4.  Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections.

Authors:  G A Linde; L Hammarström; M A Persson; C I Smith; V A Sundqvist; B Wahren
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

5.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

6.  Predominance of immunoglobulin G sub-class 3 among the complement-fixing antibodies to streptococcal M-associated protein.

Authors:  G E Mortimer; J P Widdowson
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

7.  Differences in anti-protein A activity among IgG subgroups.

Authors:  G Kronvall; R C Williams
Journal:  J Immunol       Date:  1969-10       Impact factor: 5.422

8.  Determination of varicella immunity by the indirect immunofluorescence test in urgent clinical situations.

Authors:  M Grandien; P Appelgren; A Espmark; K Hanngren
Journal:  Scand J Infect Dis       Date:  1976

9.  Immobilization of viral antigens on filter paper for a [125I]staphylococcal protein A immunoassay: a rapid and sensitive technique for detection of herpes simplex virus antigens and antiviral antibodies.

Authors:  P H Cleveland; D D Richman; M N Oxman; M G Wickham; P S Binder; D M Worthen
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

10.  Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies.

Authors:  W F Riesen; F Skvaril; D G Braun
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487
View more
  36 in total

1.  B-cell epitopes of varicella-zoster virus glycoprotein II.

Authors:  A Kjartansdóttir; E Lycke; S R Norrby
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves' hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies.

Authors:  F Latrofa; D Ricci; L Montanelli; P Piaggi; B Mazzi; F Bianchi; F Brozzi; P Santini; E Fiore; M Marinò; M Tonacchera; P Vitti
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia.

Authors:  C M Brown; C Plater-Zyberk; R A Mageed; R Jefferis; R N Maini
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

4.  IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.

Authors:  K Ljunggren; P A Broliden; L Morfeldt-Månson; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

5.  Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults.

Authors:  D K Wagner; D L Nelson; E E Walsh; C B Reimer; F W Henderson; B R Murphy
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

6.  Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants.

Authors:  P J Watt; M Zardis; P R Lambden
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

7.  Enzyme immunoassay for anti-hepatitis B core (HBc) immunoglobulin G1 and significance of low-level results in competitive assays for anti-HBc.

Authors:  M Sällberg; L O Magnius
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

8.  Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

Authors:  I Julkunen; P Ukkonen; M Stenvik; T Hovi; L Renkonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

9.  Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity.

Authors:  G A Linde; M Granström; C Orvell
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

10.  Immunoglobulin G subclass responses against the structural components of Puumala virus.

Authors:  A Lundkvist; S Björsten; B Niklasson
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.